TABLE 3.
Immunogenicity and protective efficacy of a WN candidate vaccine in leukopenic golden hamsters based on challenge with wild-type WN virus
| Group | Immunogens | Cyclophosphamide treatment | WNV reciprocal geometric mean titers (±95% CI) prior to challenge |
Survival |
|||
|---|---|---|---|---|---|---|---|
| CF | HI | PRNT | No. survivals/total | Percentage | |||
| 1 | 1µg WN–80E | + | 84 (43–125) | 70 (29–111) | 192 (24–360) | 6/15 | 40 |
| 2 | 1µg WN–80E + 1 µg NS1 | + | 53 (12–94) | 50 (11–89) | 279 (175–383) | 5/15 | 33 |
| 3 | 1µg WN–80E + 5 µg NS1 | + | 61 (34–86) | 61 (40–82) | 243 (92–394) | 8/15 | 53 |
| 4 | 5µg WN–80E | + | 153 (142–164) | 88 (74–102) | 508 (290–726) | 10/15 | 67 |
| 5 | 5µg WN–80E + 1 µg NS1 | + | 101 (74–128) | 73 (48–98) | 442 (264–620) | 12/15 | 80 |
| 6 | 5µg WN–80E + 5 µg NS1 | + | 96 (72–120) | 80 (56–104) | 368 (215–521) | 11/15 | 73 |
| 7 | Mock (adjuvant control) | + | < 10 | < 10 | < 20 | 0/10 | 0 |
| 8 | Mock (control of leukopenia) | + | < 10 | < 10 | < 20 | 10/10 | 100 |
| 9 | Mock (adjuvant control) | − | < 10 | < 10 | < 20 | 3/3 | 100 |